Research programme: G protein-coupled receptor modulators - Alchemia/Ogeda

Drug Profile

Research programme: G protein-coupled receptor modulators - Alchemia/Ogeda

Latest Information Update: 18 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alchemia; Euroscreen
  • Developer Alchemia; Ogeda
  • Class Small molecules
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Chronic obstructive pulmonary disease; Obesity
  • No development reported Diabetes mellitus; Inflammation; Pain; Rheumatoid arthritis

Most Recent Events

  • 16 May 2017 Ogeda has been acquired by and became a wholly-owned subsidiary of Astellas Pharma
  • 19 Oct 2016 Euroscreen is now called Ogeda
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-mellitus in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top